UniSuper Management 13F: Adds $40M to Eli Lilly and (LLY) Stake

On October 26, 2026, UniSuper Management boosted its stake in Eli Lilly and Company (LLY) by 34,948 shares, bringing its total to 228,947 shares worth about $264.9 million. This information comes from the fund's latest Form 13F filing with the SEC.

The increase represents an 18.0% change in UniSuper's position. The fund's total reported value for Eli Lilly now stands at approximately $11.5 billion, making up 2.31% of its total portfolio, ranked 10th among its holdings.

LLY Eli Lilly and Company

$1,279.14 ▲ +18.97% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Other Institutional Activity in Eli Lilly

Anderson Hoagland increased its holdings by 860 shares, totaling 23,796 shares valued at about $31.1 million. Signaturefd also added 961 shares, bringing its total to 27,035 shares worth approximately $31.3 million. Lilly Endowment, Inc. reduced its stake by 307,272 shares, now holding 90,066,978 shares valued at around $115.2 billion.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly shares recently traded around $1,279.16, which is about equal to the closing price of $1,279.14 on October 26. The stock is currently above its 50-day moving average by 7.8% and its 200-day moving average by 17.9%. However, it remains below its 52-week high of $1,321.21.

Recent Earnings

Eli Lilly reported a trailing twelve-month revenue of approximately $79.7 billion and an EPS of $29.79. The company’s next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Eli Lilly and Company

On August 7, 2026, Anat Hakim, General Counsel, sold 5,000 shares at an average price of $1,190, totaling $5.95 million. Officer Donald A Zakrowski sold 2,000 shares on August 10 at an average price of $1,185.01, which amounted to about $2.37 million. Officer Patrik Jonsson sold 6,500 shares on August 17 at an average price of $1,175.10, worth approximately $7.6 million.

Analysts Set New Price Targets

On September 28, 2026, JP Morgan maintained an Overweight rating on Eli Lilly with a price target of $1,500. Morgan Stanley also kept an Overweight rating with a target of $1,430 on October 7, 2026. The consensus recommendation for Eli Lilly is to buy, with a mean price target of $1,331.55 based on 30 analyst opinions.

About Eli Lilly

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company's innovative treatments span various medical conditions, making it a significant player in the healthcare sector.

Bottom Line

Investors should keep an eye on Eli Lilly's upcoming earnings report on October 29, 2026, as well as any future filings from UniSuper Management. The fund's recent increase in its stake reflects confidence in Eli Lilly's growth potential amid a competitive market.